4//SEC Filing
Valle Franco 4
Accession 0000899243-21-001847
CIK 0001731831other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:05 PM ET
Size
13.8 KB
Accession
0000899243-21-001847
Insider Transaction Report
Form 4
Valle Franco
Senior Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2021-01-11$7.24/sh+1,500$10,860→ 1,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-12−1,747→ 24,350 totalExercise: $7.24Exp: 2028-05-06→ Common Stock (1,747 underlying) - Sale
Common Stock
2021-01-12$125.44/sh−1,747$219,152→ 0 total - Sale
Common Stock
2021-01-11$125.61/sh−1,500$188,408→ 0 total - Exercise/Conversion
Common Stock
2021-01-12$7.24/sh+1,747$12,648→ 1,747 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-11−1,500→ 26,097 totalExercise: $7.24Exp: 2028-05-06→ Common Stock (1,500 underlying)
Footnotes (1)
- [F1]The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer.
Documents
Issuer
Eidos Therapeutics, Inc.
CIK 0001731831
Entity typeother
Related Parties
1- filerCIK 0001699848
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 4:05 PM ET
- Size
- 13.8 KB